- Business
- Anhui Guangxin Agrochemical Co., Ltd. (603599.SS) engages primarily in the research, development, production, and sales of pesticides and phosgene-based intermediates. The company offers a comprehensive range of pesticide technical materials and formulations, including fungicides such as carbendazim, thiophanate-methyl, azoxystrobin, pyraclostrobin, and famoxadone; herbicides such as diuron, glyphosate, and hexazinone; insecticides; and fine chemical intermediates including o-phenylenediamine, salicylonitrile, methyl cyanocarbamate, isocyanate, p-nitrochlorobenzene, and p-aminophenol, which serve the pesticide, pharmaceutical, and dye industries. It operates two major production facilities in Guangde County and Dongzhi Economic Development Zone, both in Anhui Province, China, distributing products to domestic markets and exporting approximately 70% to Europe, America, Southeast Asia, and other regions as a strategic supplier to global firms like FMC, Corteva, Helm AG, Nippon Soda Group, and Taiwan Xingnong Company.
Founded in 2000 and headquartered in the Fine Chemical Industrial Park, Guangde County, Xuancheng City, Anhui Province, China, the company ranks among China's top 14 pesticide sales firms and top 20 pesticide exporters. Anhui Guangxin targets agricultural sectors with environmentally focused agrochemical solutions, maintaining leading positions as China's largest producer of carbendazim, thiophanate-methyl, and diuron, alongside significant glyphosate output.
In recent developments, the company announced in November 2025 plans to inject its pesticide and intermediates-related assets, valued at RMB 4.383 billion, into wholly-owned subsidiary Chengchen Technology via capital increase to RMB 200 million, aiming to streamline operations. It conducted a private placement through subsidiary Anhui Dongzhi Guangxin Agrochemical Co., Ltd. in December 2024 and initiated a share buyback program for up to 5 million shares valued at CNY 100 million in early 2025. Earlier efforts included a terminated equity acquisition of 70% in Liaoning Shixing Pharmaceutical & Chemical Co., Ltd. in January 2024 and pursuits of projects like a 20,000 t/a 3,4-dichloroaniline facility in Dongzhi in 2023. Additionally, discussions emerged in April 2025 for a $300 million industrial park investment in Kenya focused on chemical production.